Zobrazeno 1 - 10
of 239
pro vyhledávání: '"Toshihiro, Nanki"'
Autor:
Zento Yamada, Sei Muraoka, Mai Kawazoe, Wataru Hirose, Hajime Kono, Shinsuke Yasuda, Takahiko Sugihara, Toshihiro Nanki
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-12 (2024)
Abstract Background We aimed to reveal the effect of abatacept (ABT) on atherosclerosis in rheumatoid arthritis (RA) patients, 3-year efficacy for arthritis, and safety in a population of older vs. younger patients. Methods In this open-label, prospe
Externí odkaz:
https://doaj.org/article/66bd378468e44200b0483f51d774dde9
Autor:
Hiroaki Dobashi, Hiroshi Sato, Sei Muraoka, Toshihiro Nanki, Nobuyuki Yajima, Eri Watanabe, Junko Nishio, Mai Kawazoe, Risa Wakiya, Soichi Yamada, Shotaro Masuoka, Tomoki Hayashi, Satoshi Mizutani, Zento Yamada, Keiko Koshiba, Izumi Irita, Miwa Kanaji, Karin Furukawa, Wataru Hirose
Publikováno v:
Lupus Science and Medicine, Vol 10, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/6de251f5bf9d46c089b16bd5f9423077
Autor:
Zento Yamada, Junko Nishio, Kaori Motomura, Satoshi Mizutani, Soichi Yamada, Tetuo Mikami, Toshihiro Nanki
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/e0a4c6f452bf406b9f56976d88fb4e8f
Autor:
Wataru Hirose, Masayoshi Harigai, Koichi Amano, Toshihiko Hidaka, Kenji Itoh, Kazutoshi Aoki, Masahiro Nakashima, Hayato Nagasawa, Yukiko Komano, Toshihiro Nanki, for the TOF-ABT Study Group
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Objectives The aim of this study was to compare the clinical effectiveness of tofacitinib and abatacept and clarify the impact of the HLA-DRB1 shared epitope (SE) on responses to these treatments in patients with rheumatoid arthritis (RA). M
Externí odkaz:
https://doaj.org/article/8072e3ec640d40be86ca5bbb0e68cc83
Autor:
Zento Yamada, Junko Nishio, Kaori Motomura, Satoshi Mizutani, Soichi Yamada, Tetuo Mikami, Toshihiro Nanki
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Fibrosing interstitial lung disease (ILD) develops due to the impaired reparative processes following lung tissue damage. Cellular senescence has been reported to contribute to the progression of fibrosis. However, the mechanisms by which these senes
Externí odkaz:
https://doaj.org/article/212c6f6252094cf9b8e7e53e0c232a38
Autor:
Waka Yokoyama-Kokuryo, Hayato Yamazaki, Tsutomu Takeuchi, Koichi Amano, Jun Kikuchi, Tsuneo Kondo, Seiji Nakamura, Ryoko Sakai, Fumio Hirano, Toshihiro Nanki, Ryuji Koike, Masayoshi Harigai
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-8 (2020)
Abstract Background Abatacept (ABA) is a biological disease-modifying antirheumatic drug (bDMARD) for rheumatoid arthritis (RA). The aim of this study was to identify molecules that are associated with therapeutic responses to ABA in patients with RA
Externí odkaz:
https://doaj.org/article/9a125c5b757142cdaea09bf9238f9372
Autor:
Shotaro Masuoka, Takashi Tanaka, Miwa Kanaji, Karin Furukawa, Keiko Koshiba, Zento Yamada, Eri Watanabe, Mai Kawazoe, Shun Ito, Ayako Fuchigami, Toshihiro Nanki
Publikováno v:
Modern Rheumatology Case Reports; Jul2024, Vol. 8 Issue 2, p280-285, 6p
Autor:
Chie Miyabe, Yoshishige Miyabe, Jun Nagai, Noriko N. Miura, Naohito Ohno, Jerold Chun, Ryoji Tsuboi, Hiroshi Ueda, Masayuki Miyasaka, Nobuyuki Miyasaka, Toshihiro Nanki
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-8 (2019)
Abstract Background Lysophosphatidic acid (LPA), generated by autotaxin (ATX), is a bioactive lipid mediator that binds to the receptors (LPA1–6), and serves as an important mediator in inflammation. Previous studies have demonstrated that LPA-LPA1
Externí odkaz:
https://doaj.org/article/803f59268f734de2931102b176b27043
Autor:
Soichi Yamada, Shion Miyoshi, Junko Nishio, Satoshi Mizutani, Zento Yamada, Natsuko Kusunoki, Hiroshi Sato, Yoshikazu Kuboi, Kana Hoshino-Negishi, Naoto Ishii, Toshio Imai, Tetsuo Mikami, Hiroyasu Nakano, Shinichi Kawai, Toshihiro Nanki
Publikováno v:
European Journal of Inflammation, Vol 18 (2020)
Background: Treatment for interstitial pneumonia (IP) associated with collagen diseases has not been established. There is a need to elucidate the pathogenesis of IP and develop a novel therapy. We aimed to clarify the role of chemokine (C-X3-C motif
Externí odkaz:
https://doaj.org/article/48e60c0fad3a48ec963e241e13797b31
Publikováno v:
Pharmaceuticals, Vol 14, Iss 12, p 1256 (2021)
Coronavirus disease 2019 (COVID-19) remains a global threat to humanity. Its pathogenesis and different phases of disease progression are being elucidated under the pandemic. Active viral replication activates various immune cells and produces large
Externí odkaz:
https://doaj.org/article/dca4ba61b62f4a179df02a25fbc46379